Nature Communications (Jan 2020)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
- Meenu Sharma,
- Hiep Khong,
- Faisal Fa’ak,
- Salah-Eddine Bentebibel,
- Louise M. E. Janssen,
- Brent C. Chesson,
- Caitlin A. Creasy,
- Marie-Andrée Forget,
- Laura Maria S. Kahn,
- Barbara Pazdrak,
- Binisha Karki,
- Yared Hailemichael,
- Manisha Singh,
- Christina Vianden,
- Srinivas Vennam,
- Uddalak Bharadwaj,
- David J. Tweardy,
- Cara Haymaker,
- Chantale Bernatchez,
- Shixia Huang,
- Kimal Rajapakshe,
- Cristian Coarfa,
- Michael E. Hurwitz,
- Mario Sznol,
- Patrick Hwu,
- Ute Hoch,
- Murali Addepalli,
- Deborah H. Charych,
- Jonathan Zalevsky,
- Adi Diab,
- Willem W. Overwijk
Affiliations
- Meenu Sharma
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Hiep Khong
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Faisal Fa’ak
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Salah-Eddine Bentebibel
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Louise M. E. Janssen
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Brent C. Chesson
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Caitlin A. Creasy
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Marie-Andrée Forget
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Laura Maria S. Kahn
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Barbara Pazdrak
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Binisha Karki
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Yared Hailemichael
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Manisha Singh
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Christina Vianden
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Srinivas Vennam
- Nektar Therapeutics
- Uddalak Bharadwaj
- Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center
- David J. Tweardy
- Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center
- Cara Haymaker
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Chantale Bernatchez
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Shixia Huang
- Department of Molecular and Cellular Biology, Baylor College of Medicine
- Kimal Rajapakshe
- Department of Molecular and Cellular Biology, Baylor College of Medicine
- Cristian Coarfa
- Department of Molecular and Cellular Biology, Baylor College of Medicine
- Michael E. Hurwitz
- Yale Comprehensive Cancer Center
- Mario Sznol
- Yale University Cancer Center, Yale University
- Patrick Hwu
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Ute Hoch
- Nektar Therapeutics
- Murali Addepalli
- Nektar Therapeutics
- Deborah H. Charych
- Nektar Therapeutics
- Jonathan Zalevsky
- Nektar Therapeutics
- Adi Diab
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- Willem W. Overwijk
- Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-14471-1
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
Interleukin-2 can induce an anti-tumour response, but is associated with toxicity. Here, the authors demonstrate that an engineered interleukin-2 promotes intratumoral T regulatory cell depletion while enhancing effective anti-tumour CD8+ T cell responses that result in potent tumor suppression.
